Evolving Testing and Treatment Strategies in Metastatic Colorectal Cancer

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.